Drew Ranieri
Stock Analyst at Morgan Stanley
(1.22)
# 3,651
Out of 4,966 analysts
167
Total ratings
45.56%
Success rate
-12.5%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Overweight | $75 → $68 | $61.27 | +10.98% | 13 | Jul 15, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $5.15 | +16.50% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $15.90 | -37.11% | 10 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $391.41 | +13.69% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $16.67 | +13.98% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $15.13 | +78.45% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $7.34 | +8.99% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $23.01 | -4.39% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $9.15 | -12.57% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $13.91 | +493.10% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $21.18 | +79.41% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $54.54 | +76.02% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.94 | +117.76% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $192.98 | +52.87% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $126.41 | +121.50% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $7.40 | -32.43% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $24.69 | +183.52% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $473.30 | -36.61% | 6 | Apr 25, 2022 |
Globus Medical
Jul 15, 2025
Maintains: Overweight
Price Target: $75 → $68
Current: $61.27
Upside: +10.98%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $5.15
Upside: +16.50%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $15.90
Upside: -37.11%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $391.41
Upside: +13.69%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $16.67
Upside: +13.98%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $15.13
Upside: +78.45%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $7.34
Upside: +8.99%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $23.01
Upside: -4.39%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $9.15
Upside: -12.57%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $13.91
Upside: +493.10%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $21.18
Upside: +79.41%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $54.54
Upside: +76.02%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.94
Upside: +117.76%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $192.98
Upside: +52.87%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $126.41
Upside: +121.50%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $7.40
Upside: -32.43%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $24.69
Upside: +183.52%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $473.30
Upside: -36.61%